Ceapro Inc (CRPOF) 0.9762 $CRPOF
Ceapro Inc. Announces Brokered Private Placement
Marketwire Canada - Thu Jun 09, 6:06AM CDT
EDMONTON, ALBERTA--(Marketwired - Jun 9, 2016) - Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has appointed Echelon Wealth Partners Inc. ("Echelon" or the "Agent" as sole agent to undertake a brokered private placement financing, on a commercially reasonable basis, of 4,716,981 units (each, a "Unit" at a price of $1.06 per Unit for gross proceeds to the Company of $5,000,000 (the "Offering".
CZO.VN: 1.240 (-0.050)
Ceapro Announces Election of Directors at 2016 Shareholders' Meeting
Marketwired - Thu Jun 02, 3:06PM CDT
EDMONTON, ALBERTA--(Marketwired - Jun 2, 2016) - Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors, Mr. Gilles Gagnon, Dr. Ulrich Kosciessa, Dr. William W. Li, Mr. Don Oborowsky, Mr. Glenn R. Rourke and Mr. John Zupancic, were elected to serve for a one-year term at its annual meeting of shareholders held on June 1, 2016.
CZO.VN: 1.240 (-0.050)
Ceapro Inc. Reports 2016 First Quarter Financial Results and Provides Corporate Update
Marketwired - Wed May 18, 7:03AM CDT
Ceapro Posts Highest Quarterly Revenues Reported in Company's History
CZO.VN: 1.240 (-0.050)
Ceapro Inc. Presents Its PGX Technology at the 15th European Meeting on Supercritical Fluids
Marketwired - Mon May 09, 7:03AM CDT
EDMONTON, ALBERTA--(Marketwired - May 9, 2016) - Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that it presented this morning its PGX Technology at the 15th European Meeting on Supercritical Fluids being held in Essen, Germany.
CZO.VN: 1.240 (-0.050)
Ceapro Inc. Provides 2015 Business Highlights and 2016 Business Outlook
Marketwired - Mon Apr 18, 6:35AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today provided a business update for the year ended December 31, 2015 and a 2016 business outlook.
CZO.VN: 1.240 (-0.050)
Ceapro Inc. Reports 2015 Financial Results, Best Financial Year in Company's History
Marketwired - Thu Apr 14, 6:36AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for the twelve-months ended December 31, 2015. The Company's 2015 Financial Results reveal the best year in Ceapro's history.
CZO.VN: 1.240 (-0.050)
Ceapro Announces Renewal of a Long Term License and Distribution Agreement With Symrise
Marketwired - Wed Apr 06, 6:05AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or "the Company" a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the signing of a new long term agreement with German-based multinational, Symrise AG, for the distribution and commercialization of Ceapro's high value active ingredients to major key international players in the cosmetic market.
CZO.VN: 1.240 (-0.050)
Ceapro Inc. Issued U.S. Patent for Enabling Pressurized Gas Expanded (PGX) Technology
Marketwired - Wed Feb 03, 7:03AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that the Company has received issuance from the U.S. Patent and Trademark Office ("USPTO" for U.S. Patent No. 13/638,254 titled, "Supercritical Fluid Treatment of High Molecular Weight Biopolymers."
CZO.VN: 1.240 (-0.050)
Ceapro to Present at Noble Financial Capital Markets' 12th Annual Investor Conference
Marketwired - Wed Jan 13, 7:03AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it will present at NobleCon12, the Noble Financial Capital Markets' 12th Annual Investor Conference, on Tuesday, January 19, 2016 at 2:30 p.m. ET in Sandpiper Bay, FL.
CZO.VN: 1.240 (-0.050)
Ceapro to Present at Biotech Showcase(TM) 2016 on January 12, 2016
Marketwired - Tue Jan 05, 7:03AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it will present at the 8th Annual Biotech Showcase(TM) conference on Tuesday, January 12, 2016 at 3:30 p.m. PT in San Francisco, CA.
CZO.VN: 1.240 (-0.050)
Ceapro Announces Issuance of Shares for Debt Reduction Initiative
Marketwired - Thu Dec 24, 6:01AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that pursuant to debt settlement agreements with each of its Directors, previously announced on December 3, 2015, it has received approval from the TSX Venture Exchange and it has issued 273,540 common shares to fully settle the debt. The settlement shares are subject to a statutory hold period of four months plus a day in accordance with applicable securities law legislation.
CZO.VN: 1.240 (-0.050)
Ceapro Inc. Announces Brokered Private Placement
Marketwire Canada - Thu Jun 09, 6:06AM CDT
EDMONTON, ALBERTA--(Marketwired - Jun 9, 2016) - Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has appointed Echelon Wealth Partners Inc. ("Echelon" or the "Agent" as sole agent to undertake a brokered private placement financing, on a commercially reasonable basis, of 4,716,981 units (each, a "Unit" at a price of $1.06 per Unit for gross proceeds to the Company of $5,000,000 (the "Offering". CZO.VN: 1.240 (-0.050)
Ceapro Announces Election of Directors at 2016 Shareholders' Meeting
Marketwired - Thu Jun 02, 3:06PM CDT
EDMONTON, ALBERTA--(Marketwired - Jun 2, 2016) - Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors, Mr. Gilles Gagnon, Dr. Ulrich Kosciessa, Dr. William W. Li, Mr. Don Oborowsky, Mr. Glenn R. Rourke and Mr. John Zupancic, were elected to serve for a one-year term at its annual meeting of shareholders held on June 1, 2016. CZO.VN: 1.240 (-0.050)
Ceapro Inc. Reports 2016 First Quarter Financial Results and Provides Corporate Update
Marketwired - Wed May 18, 7:03AM CDT
Ceapro Posts Highest Quarterly Revenues Reported in Company's History
CZO.VN: 1.240 (-0.050)
Ceapro Inc. Presents Its PGX Technology at the 15th European Meeting on Supercritical Fluids
Marketwired - Mon May 09, 7:03AM CDT
EDMONTON, ALBERTA--(Marketwired - May 9, 2016) - Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that it presented this morning its PGX Technology at the 15th European Meeting on Supercritical Fluids being held in Essen, Germany. CZO.VN: 1.240 (-0.050)
Ceapro Inc. Provides 2015 Business Highlights and 2016 Business Outlook
Marketwired - Mon Apr 18, 6:35AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today provided a business update for the year ended December 31, 2015 and a 2016 business outlook. CZO.VN: 1.240 (-0.050)
Ceapro Inc. Reports 2015 Financial Results, Best Financial Year in Company's History
Marketwired - Thu Apr 14, 6:36AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for the twelve-months ended December 31, 2015. The Company's 2015 Financial Results reveal the best year in Ceapro's history. CZO.VN: 1.240 (-0.050)
Ceapro Announces Renewal of a Long Term License and Distribution Agreement With Symrise
Marketwired - Wed Apr 06, 6:05AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or "the Company"
a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the signing of a new long term agreement with German-based multinational, Symrise AG, for the distribution and commercialization of Ceapro's high value active ingredients to major key international players in the cosmetic market. CZO.VN: 1.240 (-0.050)
Ceapro Inc. Issued U.S. Patent for Enabling Pressurized Gas Expanded (PGX) Technology
Marketwired - Wed Feb 03, 7:03AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that the Company has received issuance from the U.S. Patent and Trademark Office ("USPTO" for U.S. Patent No. 13/638,254 titled, "Supercritical Fluid Treatment of High Molecular Weight Biopolymers." CZO.VN: 1.240 (-0.050)
Ceapro to Present at Noble Financial Capital Markets' 12th Annual Investor Conference
Marketwired - Wed Jan 13, 7:03AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it will present at NobleCon12, the Noble Financial Capital Markets' 12th Annual Investor Conference, on Tuesday, January 19, 2016 at 2:30 p.m. ET in Sandpiper Bay, FL. CZO.VN: 1.240 (-0.050)
Ceapro to Present at Biotech Showcase(TM) 2016 on January 12, 2016
Marketwired - Tue Jan 05, 7:03AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it will present at the 8th Annual Biotech Showcase(TM) conference on Tuesday, January 12, 2016 at 3:30 p.m. PT in San Francisco, CA. CZO.VN: 1.240 (-0.050)
Ceapro Announces Issuance of Shares for Debt Reduction Initiative
Marketwired - Thu Dec 24, 6:01AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that pursuant to debt settlement agreements with each of its Directors, previously announced on December 3, 2015, it has received approval from the TSX Venture Exchange and it has issued 273,540 common shares to fully settle the debt. The settlement shares are subject to a statutory hold period of four months plus a day in accordance with applicable securities law legislation. CZO.VN: 1.240 (-0.050)
